We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Pfizer Inc | NYSE:PFE | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.12 | -0.42% | 28.52 | 28.71 | 28.46 | 28.66 | 22,510,301 | 00:53:43 |
From May 2021 to May 2024
By Colin Kellaher
Pfizer Inc. and BioNTech SE on Thursday said a Phase 3 study showed a booster dose of their Covid-19 vaccine in individuals 16 years of age and older saw a relative vaccine efficacy of 95.6% compared to those who didn't receive a booster.
The partners said a booster dose administered to those who had already received the primary two-dose series of their vaccine restored protection against Covid-19 to the high levels achieved after the second dose.
Pfizer and BioNTech said they plan to submit the data to regulatory agencies around the world to support licensure in the U.S. and other countries.
The U.S. Food and Drug Administration in September granted emergency approval of a third dose of the Pfizer/BioNTech vaccine for people 65 and older and certain other adults at high risk of severe illness. The agency Wednesday cleared the use of a booster dose in eligible individuals who completed a primary round with a different vaccine.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 21, 2021 07:34 ET (11:34 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Pfizer Chart |
1 Month Pfizer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
